Category: CovidienSyndicate content

Another Covidien shareholder sues to block Medtronic merger

August 12, 2014 by Brad Perriello

Another Covidien shareholder sues to block the pending, $43 billion merger with Medtronic, arguing that the deal violates both American and Irish laws.

Another Covidien shareholder sues to block Medtronic merger

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Medtronic-Covidien merger means tax hit for all stockholders, including execs

August 11, 2014 by Arezu Sarvestani

The terms of Medtronic's unusual $43 billion acquisition of Covidien means that all MDT shareholders are subject to paying a capital gains tax, including executives and board members.

Medtronic-Covidien merger means tax hit for all stockholders, including execs

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Medtronic hires ex-Senators to lobby for Covidien deal

August 11, 2014 by Arezu Sarvestani

Medtronic engages former Senators Trent Lott and John Breaux to lobby on behalf of the company's $43 billion acquisition of Covidien and its subsequent move overseas.

Medtronic hires former Senators to lobby on Covidien deal

Medtech titan Medtronic (NYSE:MDT) has a few heavy-hitters in its corner during its fight against anti-corporate inversion measures on Capitol Hill.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

FTC wants more data on Medtronic-Covidien deal, but analysts aren't worried

August 7, 2014 by Arezu Sarvestani

Despite the furor on Capitol Hill, lawmakers aren't likely to produce reform that will hinder Medtronic's $43 billion acquisition of Covidien, according to Morgan Stanley analysts.

Analyst report: Dems can't stop Medtronic-Covidien merger

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Lack of FDA approval is no longer a deal-breaker for a big exit | The week in medtech M&A

August 6, 2014 by MassDevice

Here's a look at some of the top regulatory stories for medical device companies this week: Report: Medtech M&A exits don't hinge on FDA approval; White House rails against Medtronic-style corporate inversions; Smith & Nephew CEO: We've been an M&A target for 10 years; More mega-merger talk from medtech giants; Baxter sheds vaccines biz for $635M

Report: Medtech M&A exits don't hinge on FDA approval

July 31, 2014 by Arezu Sarvestani

Report: Medtech M&A no longer hinges on FDA approval

Details of the mega-merger: Covidien makes the 1st move, Almeida prepares to step down

August 6, 2014 by Arezu Sarvestani

Covidien discloses details of the pending $43 billion acquisition by Medtronic, including who approached who and what Covidien chief Jose Almeida will do after handing the reins to Medtronic.

Medtronic and Covidien open up about $43B mega-merger

Congress moves to punish Medtronic and other 'corporate deserters'

August 5, 2014 by Arezu Sarvestani

Democrats in the Senate and House push a measure to withhold federal contracts from companies that move their headquarters overseas to find better corporate tax rates.

Senate moves to punish Medtronic and other 'corporate deserts'

A handful of Democrats in Congress are hoping to curb a corporate exodus by threatening to withhold federal contracts from firms that shift their headquarters overseas to benefit from lower tax rates.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp